Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241914780 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von María Antonia Pérez-Moreno und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University Hospital Virgen del Rocío, 41013 Seville, Spain. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The aim of this paper was to review the available evidence on the efficacy and safety of combined or sequential use of PD-1/PD-L1 immune checkpoint inhibitors (ICI) and CAR-T cell therapies in relapsed/refractory (R/R) haematological malignancies. A systematic literature review was performed until 21 November 2022. Inclusion criteria: cohort studies/clinical trials aimed at evaluating the efficacy and/or safety of the combination of CAR-T cell therapy with PD-1/PD-L1 inhibitors in R/R haematological malignancies, which had reported results. Those focusing only on ICI or CAR-T separately or evaluating the combination in other non-hematological solid tumours were excluded. We used a specific checklist for quality assessment of the studies, and then we extracted data on efficacy or efficiency and safety. A total of 1867 articles were identified, and 9 articles were finally included (early phase studies, with small samples of patients and acceptable quality). The main pathologies were B-cell acute lymphoblastic leukaemia (B-ALL) and B-cell non-Hodgkin’s lymphoma (B-NHL). The most studied combination was tisagenlecleucel with pembrolizumab. In terms of efficacy, there is great variability: the combination could be a promising option in B-ALL, with modest data, and in B-NHL, although hopeful responses were received, the combination does not appear better than CAR-T cell monotherapy. The safety profile could be considered comparable to that described for CAR-T cell monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University Hospital Virgen del Rocío, 41013 Seville, Spain.
- Department of Haematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, University of Seville, 41012 Seville, Spain.
- Department of Pharmacy and Pharmaceutical Technology, University of Seville, 41012 Seville, Spain.
ORCID-Profile: María Antonia Pérez-Moreno
Zitieren
APA
Pérez-Moreno, M. A., Ciudad-Gutiérrez, P., Jaramillo-Ruiz, D., Reguera-Ortega, J. L., Abdel-Kader Martín, L., & Flores-Moreno, S. (2023). Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914780
Vancouver
Pérez-Moreno MA, Ciudad-Gutiérrez P, Jaramillo-Ruiz D, Reguera-Ortega JL, Abdel-Kader Martín L, Flores-Moreno S. Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914780
BibTeX
@article{PrezMoreno2023,
author = {Pérez-Moreno, María Antonia and Ciudad-Gutiérrez, Pablo and Jaramillo-Ruiz, Didiana and Reguera-Ortega, Juan Luis and Abdel-Kader Martín, Laila and Flores-Moreno, Sandra},
title = {Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241914780}
}
EUVIMED